Expression Profile and Molecular Basis of Cyclin-Dependent Kinases Regulatory Subunit 2 in Endometrial Carcinoma Detected by Diversified Methods

Li Gao¹, Gang Chen¹, Zi-Qian Liang¹, Jian-Di Li¹, Dong-Ming Li¹, Yu-Lu Tang¹, Deng Tang¹, Zhi-Guang Huang¹, Jun-Hong Chen², Jia-Yuan Luo¹, Jiang-Hui Zeng³, Yi-Wu Dang¹ and Zhen-Bo Feng¹*

¹Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China; ²Department of Pathology, Guangxi Maternal and Child Health Hospital, Nanning, China; ³Department of Clinical Laboratory, The Third Affiliated Hospital of Guangxi Medical University/Nanning Second People’s Hospital, Nanning, China

Purpose: Our purpose was to systematically appraise the clinicopathological significance and explore the molecular bases of CKS2 in endometrial carcinoma.

Patients and Methods: We measured the clinicopathological significance of CKS2 using diverse methods of public RNA-seq, microarrays, and in-house tissue microarrays to investigate the molecular basis of CKS2 in endometrial carcinoma through upstream transcriptional analysis, immune infiltration correlation analysis, and co-expression analysis.

Results: Both the analysis for public RNA-seq plus the microarray data and in-house tissue microarray confirmed the significant overexpression of CKS2 in a total of 1,021 endometrial carcinoma samples compared with 279 non-cancer endometrium samples (SMD = 2.10, 95% CI = 0.72–3.48). The upregulated CKS2 was significantly related to the lymph node metastasis and advanced clinical grade of endometrial carcinoma patients (p < 0.001). Mutation types such as amplification and mRNA occurred with high frequency in the CKS2 gene in endometrial carcinoma patients. A series of miRNAs and transcription factors, such as hsa-miR-26a, hsa-miR-130a, hsa-miR-30, E2F4, MAX, and GABPA, were predicted to regulate the transcription and expression of CKS2. Significant links were found between CKS2 expression and the infiltration level of B cells, CD4+ T cells, and neutrophils in endometrial carcinoma. CKS2–coexpressed genes were actively involved in pathways such as the mitotic cell cycle process, PID aurora B pathway, and prolactin signaling pathway.

Conclusion: The overexpressed CKS2 showed positive correlations with the clinical progression of endometrial carcinoma and was associated with various cancer-related

Abbreviations: AUC, area under the curve; CKS2, cyclin-dependent kinases regulatory subunit 2; DEG, differentially expressed gene; GEO, Gene Expression Omnibus; GO, gene ontology; GTEx, Genotype-Tissue Expression; HR, hazard ratio; IHC, immunohistochemistry; SMD, standard mean difference; SROC, summarized receiver operating characteristics; TCGA, The Cancer Genome Atlas; TF, transcription factor; TIMER, Tumor Immune Estimation Resource; TPM, transcripts per million.
INTRODUCTION

As one of the most common malignancies of the female reproductive system, endometrial carcinoma caused over 417,000 newly diagnosed cases and over 97,000 deaths in 2020 [1]. In parallel with the increased rate of obesity and the growing aging female population, the incidence of endometrial carcinoma continues to rise [2, 3]. Based on clinical and histological characteristics, endometrial carcinoma was classified into type I and type II [4]. While obesity and high levels of estrogen were linked with type I endometrial carcinoma, which accounted for the majority of endometrial carcinoma and showed relatively good differentiation, type II endometrial carcinoma was found to be more aggressive [5]. In current times, surgical operation consolidated by adjuvant chemotherapy and radiotherapy serves as the main treatment modality for endometrial carcinoma patients [6–8]. Although great progress made in the therapy of endometrial carcinoma has remarkably curbed the progression of endometrial carcinoma, endometrial carcinoma patients in later stage are still tortured by worsening prognoses, and recurrences were reported in some patients in the early stage [9, 10]. Such a scenario highlights the imperative of seeking novel biomarkers and other treatment strategies.

Cyclin-dependent kinases regulatory subunit 2 (CKS2) is one of the components of the cycle-dependent protein kinase subunits family that shows high conservatism in eukaryotes and plays essential roles in the regulation of the cell cycle of somatic cells and early embryogenesis [11, 12]. A growing body of evidence has indicated that CKS2 exhibited upregulation in a variety of human cancers and contributed to tumor progression [12–14]. CKS2 was reported to be overexpressed in cholangiocarcinoma and stimulate the aggressiveness of cholangiocarcinoma by modulating cell cycle progression and mitochondrial caspase-dependent apoptosis [15]. In esophageal squamous cell carcinoma, CKS2 expression was significantly higher in cancer tissues, and suppression of CKS2 attenuated the growth of esophageal squamous cell carcinoma [16]. So far, there has been no research on the overall assessment of the clinicopathological significance of CKS2 in endometrial carcinoma and the molecular basis of CKS2 in the oncogenesis of endometrial carcinoma.

Herein, we planned to systematically appraise the clinicopathological significance and explore the molecular bases of CKS2 in endometrial carcinoma using multiple detection technologies, including microarrays, RNA-seq, and in-house tissue microarrays.

MATERIALS AND METHODS

Evidence From Public Microarrays and RNA-Seq Datasets

Clinical data of endometrial carcinoma patients and gene expression values (in the data format of fragments per kilobase per million or transcripts per kilobase million) in endometrial carcinoma and non-cancer endometrium tissues were imported from the Genotype-Tissue Expression (GTEx) project and The Cancer Genome Atlas (TCGA) database. Detailed clinicopathological information on endometrial carcinoma patients from the TCGA database is listed in Supplementary Table S1. The incorporated dataset of the TCGA-GTEx expression matrix (containing 552 endometrial carcinoma and 177 non-cancer endometrium samples) was normalized by the formula of log2 (transcripts per kilobase million value +0.001). Other sources for our study’s expression analysis (Table 1) were microarray datasets in the Gene Expression Omnibus (GEO) or ArrayExpress databases, which deposit the gene expression matrix of at least three endometrial carcinoma and three non-cancer endometrium samples that belong to the human species (before 7 June 2021).

Expression Analysis for CKS2 Utilizing External RNA-Seq and Microarray Datasets

We conducted the extraction and processing of CKS2 expression data according to the methods in prior works [17]. Microarrays were aggregated by the GPL platform, and the batch effect was removed for microarrays from the same platform through the limma package loaded by R software v.3.6.1. The standard mean difference (SMD) plot was calculated for comparison of the different expressions of CKS2 in endometrial carcinoma versus non-cancer tissues, and the corresponding summarized receiver operating characteristics (SROC) curves were plotted. The steps of drawing SMD forest plots and SROC curves and be found in previous studies [18]. The expression pattern of CKS2 in endometrial carcinoma and the distinguishing ability of CKS2 expression for endometrial carcinoma were exhibited as violin plots and ROC curves for all included RNA-seq datasets and public microarrays [19, 20].

In-House Tissue Microarray

Surgical resected samples of 301 endometrial carcinoma tissues (two undifferentiated carcinoma cases, 295 endometrial endometrioid adenocarcinoma tissues, and 4 endometrioid adenocarcinoma with squamous differentiation tissues) and 38 normal endometrium tissues (date: January 2018 to June 2019) provided by Guilin Fanpu Biotech of Guangxi, China, were enrolled for the immunohistochemistry (IHC) experiment. The basic information for all included tissues is included in Supplementary Table S2. Informed consent was provided by all involved endometrial carcinoma patients, and the ethics committee of Guilin Fanpu Biotech and that of the First Affiliated Hospital of Guangxi Medical University [Approval ID: 2020 (KY-E-095)] authorized the study.

Firstly, the paraffin section was put into a 60°C oven for 120 min followed by routine dewaxing of paraffin sections. After being soaked in different concentrations of ethanol, the slides were...
### TABLE 1 | Basic information from all included RNA-seq and microarray datasets of endometrial carcinoma.

| Accession ID | Platform | Country       | First author               | Sample type | Number of tumor samples | Number of non-cancer samples | Experiment type                              | Histological type                                                                 |
|--------------|----------|---------------|----------------------------|-------------|-------------------------|----------------------------|---------------------------------------------|-----------------------------------------------------------------------------------|
| GSE17025     | GPL570   | United States | Uma Chandran               | Tissue      | 91                      | 12                         | Expression profiling by array               | Endometrioid endometrial carcinoma and serous endometrial carcinoma               |
| GSE56087     | GPL11154 | China         | Yifeng Zhou                | Tissue      | 9                       | 9                          | Expression profiling by high throughput sequencing | Not specified                                                                     |
| GSE63678     | GPL571   | United States | Prokopios Alexandros       | Tissue      | 7                       | 5                          | Expression profiling by array               | Not specified                                                                     |
| GSE115810    | GPL96    | Poland        | Urszula Mazurek Asha Nair  | Tissue      | 24                      | 3                          | Expression profiling by array               | Not specified                                                                     |
| GSE146889    | GPL16791 | United States |                           | Tissue      | 37                      | 35                         | Expression profiling by array               | Endometrioid endometrial adenocarcinoma, Serous endometrial adenocarcinoma and mixed serous and endometrioid |
| TCGA-GTEX    | —        | —             | —                          | Tissue      | 552                     | 177                        | —                                           | —                                                                                |

#### FIGURE 1 | Flowchart of inclusion of eligible microarrays and RNA-seq datasets.
rinsed with tap water for 3 min. Antigen repair was conducted on the slides with EDTA antigen repair solution (distilled water: EDTA = 50:1). Endogenous peroxidase blocker (hydrogen peroxide 30%, CAS 7722-84-1, Chengdu Kelong Chemical Co., Ltd.) (100 μl) was applied to each slide at room temperature and washed by PBS following 10 min incubation. The antibody for CKS2 (https://www.abcam.cn/cks2-antibody-epr79462-ab155078.html) and an enzyme labeled Sheep anti-rabbit IgG polymer (secondary antibody) were used for two periods of incubation. Subsequently, incubation with hematoxylin staining solution and gradient alcohol dehydration was performed. Finally, the slides were made transparent by xylene and sealed with neutral gum and coverslip. Two pathologists reviewed and assessed the immunostaining of all images under a microscope (Motic China Group Co., Ltd.) (magnification, ×200 and ×400). The scores for percentage of positively stained cells (0, <5%; 1, 5%–25%; 2, 26%–50%; 3, 51%–75%; 4, >75%) multiplied by scores for staining intensity (0, negative; 1, weak; 2, medium; 3, strong) were the final IHC scores of each slide. The range of possible scores was 0–12. An IHC score of <4 indicated low CKS2 protein expression and an IHC score of ≥4 indicated high CKS2 protein expression.

**Survival Analysis for CKS2 in Endometrial Carcinoma**

To investigate whether CKS2 expression has an impact on the overall survival of endometrial carcinoma patients or not, we plotted Kaplan-Meier survival curves using GraphPad Prism v.8.0.1 based on information from 535 endometrial carcinoma patients without adjuvant treatment from RNA-seq datasets in TCGA database. The accompanied log-rank test was performed and p < 0.05 means statistically significant.

**Landscape of Genetic Mutation of CKS2 in Endometrial Carcinoma**

We made use of the cBioPortal database to query mutation types and z-scores of mRNA expression (log RNA Seq V2 RSEM) of

---

**FIGURE 2** | CKS2 expression in endometrial carcinoma and non-cancer samples from external microarrays and RNA-seq dataset. Violin plots for GSE115810 (A), GSE146889 (B), GSE17025 (C), GSE56087 (D), GSE63678 (E) and TCGA-GTEx dataset (F). N, non-cancer endometrium samples; T, endometrial carcinoma samples.
CKS2 in 548 endometrial carcinoma samples using genomic data from the GDAC Firehose project.

Potential Up-Stream Regulatory Mechanism of CKS2
By considering the critical roles of miRNA and transcription factor (TFs) in regulating gene expression, we explored the regulatory mechanism of aberrant CKS2 expression from the aspects of miRNA and TFs. Upstream miRNAs and TFs that might control the transcription and expression of CKS2 were estimated by the miRWalk 3 and NetworkAnalyst databases.

Correlation Between CKS2 Expression and Immune Infiltration in Endometrial Carcinoma
The online tool Tumor Immune Estimation Resource (TIMER) was employed for evaluating the correlation between CKS2 expression and the infiltration level of diversified immune cells including B cells, T cells, Neutrophils, Macrophages, and Dendritic cells. Significant relationships were filtered by a $p$ value of 0.05.

Characterization of Molecular Function for CKS2-Co-Expressed Genes in Endometrial Carcinoma
We carried out differential expression analysis to compare gene expression profiles of endometrial carcinoma and non-cancer endometrium tissues from all included microarrays via limma package loaded by R software v.3.6.1. Differentially expressed genes (DEGs) in the RNA-seq dataset were calculated with a count matrix using the voom algorithm in R software v.3.6.1. DEGs of endometrial carcinoma met the conditions of showing significant upregulation ($\text{log}_{2} \text{FC} > 1$, adj. $p < 0.05$) or significant downregulation ($\text{log}_{2} \text{FC} < -1$, adj. $p < 0.05$) in at least three datasets. The associations between expression values of genes were appraised via a Pearson correlation test embedded in the psych package loaded by R software v.3.6.1. Upregulated DEGs that were positively correlated with the expression of CKS2 ($r > 0$, adjusted $p < 0.05$) in four or more datasets of endometrial carcioma.
cancer were regarded as genes positively related to CKS2 in endometrial carcinoma; genes negatively correlated with CKS2 in endometrial carcinoma were downregulated DEGs that showed negative relationship with CKS2 (adjusted \( p < 0.05, r < 0 \)) in three or more datasets. Functional enrichment of the above genes with significant relations to CKS2 was annotated through pathway analysis and gene ontology (GO). Functional annotation was conducted with MetaScape and adjusted \( p < 0.05 \) was the cutoff value for significant pathway and GO terms.

**Statistical Analysis**
SPSS 22.0 was applied for analyzing the clinicopathological significance of CKS2 in endometrial carcinoma samples from the RNA-seq dataset and in-house tissue microarrays. At last, statistical significance was indicated by \( p < 0.05 \). The Independent sample t-test was used for the comparison of CKS2 expression in two groups of clinicopathological variables. Comparison of CKS2 expression in three or more groups of clinicopathological variables was conducted through analysis of variance or Kruskal-Wallis test when normal distribution was not met.

**RESULTS**

**Distinct CKS2 Expression Between Endometrial Carcinoma and Non-Cancer Endometrium Tissues**
A total of five microarrays after the removal of batch effect and TCGA-GTEx RNA-seq datasets were included for expression analysis of CKS2 in endometrial carcinoma, the selection process of which was illustrated in Figure 1. Clinical information of all endometrial carcinoma patients from the RNA-seq dataset in the TCGA database and details of all included datasets are described in Supplementary Table S1 and Table 1. All endometrial carcinoma and non-cancer samples from public microarrays and RNA-seq datasets amounted to 720 and 241, respectively. CKS2 displayed obvious higher expression in endometrial carcinoma and a favorable distinguishing ability for endometrial carcinoma in the majority of datasets (Figure 2) (Supplementary Figure S1). SMD forest plot and SROC curves generated from all included datasets confirmed the overexpression of CKS2 in endometrial carcinoma and the capacity of upregulated CKS2 in discerning endometrial carcinoma from non-cancer endometrium tissues (SMD = 2.10, 95% CI = 0.72–3.48; AUC = 0.96) (Figure 3). Analysis of the relationships between CKS2 expression and the clinicopathological variables of endometrial carcinoma patients from the RNA-seq dataset in the TCGA database reported higher CKS2 expression in endometrial carcinoma patients with a higher grade (G3) and Black or African American patients (\( p < 0.001 \) (\( p = 0.012 \)) (Figures 4A,B) (Table 2).

Raw data related to the endometrial carcinoma patients included in tissue microarray was listed in Supplementary Table S2. As shown by the IHC staining results for 301 endometrial carcinoma and 38 non-cancer endometrium tissues, CKS2 expression was remarkably higher in the glandular epithelial cells of endometrial carcinoma tissues than in non-cancer endometrium tissue (9.071 ± 1.122; 5.789 ± 1.788, \( p < 0.001 \)) (Figure 5). The differentially expressed CKS2 also showed good performance in discriminating endometrial carcinoma from non-cancer endometrium tissues (AUC = 0.944) (Figure 5H). Moreover, endometrial carcinoma patients with lymph node metastasis presented notably higher CKS2 expression than endometrial carcinoma patients without lymph node metastasis (\( p < 0.001 \)) (Supplementary Figure S2) (Table 3).

**Influence of CKS2 Expression on the Prognosis of Endometrial Carcinoma Patients**
Kaplan-Meier survival analysis for 535 endometrial carcinoma patients without adjuvant treatment in RNA-seq dataset of TCGA database indicated no significant impact of CKS2 expression on the survival time of endometrial carcinoma patients (hazard ratio (HR) = 0.832, \( p = 0.536 \)) (Figure 4C).

**Genetic Mutation Types of CKS2 in Endometrial Carcinoma**
Four cases of amplification, four cases of deep depletion, three cases of mRNA high, and seven cases of mRNA low were displayed in the genetic alteration profiles of 548 endometrial carcinoma cases from the GDAC Firehose project of cBioPortal (Supplementary Figure S3).

**Prediction of Upstream miRNAs and TFs for CKS2**
A series of miRNAs such as has-miR-26hashsa-miR-130a, and lsa-miR-30c as well as TFs, including E2F4, MAX, and GABPA, emerged in the networks with the potential to regulate the transcription of CKS2 (Supplementary Figure S4).

**Correlation Between CKS2 Expression and Immune Infiltration in Endometrial Carcinoma**
Pearson correlation analysis results revealed that CKS2 expression was negatively linked with the infiltration level of B cell and CD4+ T cell in endometrial carcinoma (\( r = -0.125, p = 0.034, r = -0.173, p = 0.003 \)). A positive relationship was found between CKS2 expression and the infiltration level of neutrophils (\( r = 0.127, p = 0.030 \)) (Figure 6).

**Molecular Functions of CKS2-Related Genes in Endometrial Carcinoma**
Of 455 identified upregulated DEGs and 428 identified downregulated DEGs in endometrial carcinoma, 153 genes positively co-expressed with CKS2 and 101 genes negatively co-expressed with CKS2 were screened out (Figure 7A). Genes positively co-expressed with CKS2 were annotated to cluster in
biological processes and pathways including mitotic cell cycle process, microtubule cytoskeleton organization involved in mitosis, and PID aurora B pathway (Figure 7B). Biological process and pathway terms such as the circulatory system process, calcium ion transport, and the prolactin signaling pathway were prominently assembled by genes negatively co-expressed with CKS2 (Supplementary Figure S5).

DISCUSSION

The flourishing of genome sequencing and high-throughput microarrays generated huge amounts of data useful for oncolgical research. Making full use of big data and in-house molecular pathology technology, we were the first group to measure the clinicopathological significance of CKS2 in pooled multi-center endometrial carcinoma samples and to investigate the molecular basis of CKS2 in endometrial carcinoma through upstream transcriptional analysis, immune correlation analysis, and co-expression analysis.

First of all, an incorporated expression matrix from public RNA-seq and microarrays as well as data from in-house tissue microarray uniformly supported the overexpression of CKS2 in endometrial carcinoma. The reliability of the study is embodied in the large sample size of 1,021 endometrial carcinoma cases and 279 non-cancer endometrium cases. The significant associations
between CKS2 expression and lymph node metastasis or grade of endometrial carcinoma revealed by independent sample t test with the clinical-pathological parameters implied the positive links between CKS2 overexpression and the clinical progression of endometrial carcinoma. The prognostic value of CKS2 has been discovered in multiple human cancers including adrenocortical carcinoma, lung adenocarcinoma, and colorectal cancer [21–23]. However, the survival analysis in this study suggested no significant influence of CKS2 expression on prognosis of endometrial carcinoma patients; thus, whether CKS2 expression carries a prognostic value for predicting the survival time of endometrial carcinoma patients needed to be explored with larger cohorts in future studies.

Despite the fact that the carcinogenesis of endometrial carcinoma complicated genetic interactions and activities of pathways, finding an appropriate entry point would be conducive to the exploration of the mechanisms. In the present work, we investigated the molecular mechanisms of CKS2 in endometrial carcinoma via diverse methods of genetic mutation profile analysis, upstream transcriptional analysis, and clinical-pathological parameters.

### TABLE 2 | The relationship between CKS2 expression and the clinicopathological features of endometrial carcinoma patients from the RNA-seq dataset in the TCGA database.

| Clinical features      | CKS2 expression value | t     | p-value |
|------------------------|-----------------------|-------|---------|
|                        | Number | Mean | Standard deviation |       |
| Menopause status       |         |      |                   |       |
| Inter-menopause        | 17      | 7.545| 0.956             | 1.317a| 0.268   |
| Peri-menopause         | 17      | 7.360| 0.829             |       |         |
| Post-menopause         | 445     | 7.763| 0.904             |       |         |
| Pre-menopause          | 35      | 7.723| 1.146             |       |         |
| BMI                    |         |      |                   |       |         |
| <30                    | 209     | 7.795| 0.896             | 1.312 | 0.190   |
| ≥30                    | 303     | 7.688| 0.918             |       |         |
| Race                   |         |      |                   |       |         |
| American Indian or Alaska native | 4     | 7.769| 0.467             | 12.953b| 0.012   |
| Asian                  | 20      | 7.852| 1.268             |       |         |
| Black or African American | 106    | 8.002| 0.814             |       |         |
| Native Hawaiian or other Pacific islander | 9      | 7.644| 1.449             |       |         |
| White                  | 372     | 7.659| 0.899             |       |         |
| Ethnicity              |         |      |                   |       |         |
| Hispanic or Latino     | 15      | 7.751| 1.130             | 0.046 | 0.963   |
| Not Hispanic or Latino | 373     | 7.740| 0.926             |       |         |
| Neoplasm cancer status |         |      |                   |       |         |
| Tumor free             | 427     | 7.706| 0.904             | -1.484| 0.138   |
| With tumor             | 78      | 7.876| 1.055             |       |         |
| Histological type      |         |      |                   |       |         |
| Endometrioid endometrial adenocarcinoma | 407   | 7.695| 0.948             | 4.539b| 0.103   |
| Mixed serous and endometrioid | 22    | 7.742| 0.815             |       |         |
| Serous endometrial adenocarcinoma | 114   | 7.946| 0.793             |       |         |
| Age                    |         |      |                   |       |         |
| <60                    | 178     | 7.771| 0.992             | 0.372 | 0.710   |
| ≥60                    | 365     | 7.739| 0.879             |       |         |
| Peritoneal wash        |         |      |                   |       |         |
| Negative               | 350     | 7.694| 0.922             | -0.696| 0.487   |
| Positive               | 57      | 7.786| 0.919             |       |         |
| Histologic grade       |         |      |                   |       |         |
| G1-2                   | 218     | 7.406| 0.905             | -7.514| <0.001  |
| G3                     | 325     | 7.980| 0.852             |       |         |
| Residual tumor         |         |      |                   |       |         |
| R0                     | 372     | 7.735| 0.966             | 0.042a| 0.959   |
| R1                     | 22      | 7.741| 1.031             |       |         |
| R2                     | 16      | 7.665| 0.733             |       |         |
| Venous invasion        |         |      |                   |       |         |
| No                     | 40      | 4.477| 1.662             | -0.945| 0.486   |
| Yes                    | 63      | 4.829| 1.948             |       |         |
| History of birth control pill usage |         |      |                   |       |         |
| No                     | 48      | 4.545| 1.654             | -1.084| 0.280   |
| Yes                    | 100     | 4.883| 1.835             |       |         |
| Clinical stage         |         |      |                   |       |         |
| I-II                   | 390     | 7.703| 0.925             | -1.913| 0.056   |
| III-IV                 | 153     | 7.870| 0.887             |       |         |

aAnalysis of variance was performed.
bKruskal-Wallis test was performed.
immune correlation analysis, and co-expression analysis. It could be noted from the overview diagram of the genetic alteration types of CKS2 in endometrial carcinoma that amplification and mRNA high constituted the half of cases with mutation of the CKS2 gene, which might interpret the upregulation of CKS2 in endometrial carcinoma and other human cancers. In view of the critical roles of upstream regulators such as miRNAs and TFs in modulating the transcription and expression of genes, we also built the miRNAs/TFs-CKS2 networks to probe into the CKS2-centered transcriptional regulatory mechanisms. The novelty of findings in this part lies in that the interactions between CKS2 and most of the miRNAs or TFs predicted above have not been reported by research. It could be speculated that these proposed miRNAs and TFs may serve as the initiators of the oncogenic effect of CKS2 in endometrial carcinoma. With regard to the correlation between CKS2 expression and the infiltration level of immune cells in endometrial carcinoma, significant bonds were observed between CKS2 expression and the immune infiltration of B cells, CD4+ T cells, or neutrophils. It has been reported that patients with polymerase ε ultra-mutated endometrial carcinomas had better prognosis than patients with polymerase ε-wild type endometrial carcinoma and this phenomenon was linked with the activated CD4+ T cell responses in polymerase ε ultra-mutated endometrial carcinoma patients [23], from which it could be inferred that the enhanced responses of CD4+ T cells might mitigate the malignant development of endometrial carcinoma. We assumed that upregulated CKS2 might reshape the tumor

Gao et al. CKS2 in Endometrial Carcinoma
microenvironment of endometrial carcinoma by means of inhibiting the population of B cells and CD4\(^+\) T cells or increasing the population of neutrophils to contribute to the initiation and progression of endometrial carcinoma.

Lastly, we identified the CKS2-correlated genes in endometrial carcinoma via rigorous calculation of DEGs and correlation expression analysis. Functional annotation for the CKS2-correlated genes revealed a range of interesting biological processes and pathway terms. There were obvious variations between biological processes enriched by genes positively correlated with CKS2 and biological process genes negatively correlated with CKS2. While terms associated with cell cycle and DNA replication appeared with high frequency in the enrichment results for genes positively co-expressed with CKS2, the biological

### TABLE 3 | The relationship between CKS2 expression and the clinicopathological features of endometrial carcinoma patients from in-house tissue microarray.

| Clinical features                          | CKS2 expression value | \( t \) | \( p \)-value |
|--------------------------------------------|-----------------------|--------|--------------|
|                                           | Number | Mean | Standard deviation |
| Pathological classification               |        |      |                |
| Endometrioid adenocarcinoma                | 295    | 8.99 | 1.131          | 0.369* 0.691 |
| Endometrioid adenocarcinoma with squamous differentiation | 4     | 8.50 | 0.577          |        |
| Undifferentiated carcinoma                 | 2      | 9.00 | 0.000          |        |
| Age                                        |        |      |                |
| <60                                        | 238    | 8.92 | 1.088          | -1.326 0.186 |
| ≥60                                        | 56     | 9.14 | 1.146          |        |
| Histologic grade                           |        |      |                |
| G1-2                                       | 207    | 8.96 | 1.072          | -0.385 0.701 |
| G3                                         | 83     | 9.01 | 1.205          |        |
| T stage                                    |        |      |                |
| 1–2                                        | 285    | 8.94 | 1.094          | -2.098 0.052 |
| 3–4                                        | 16     | 9.69 | 1.401          |        |
| Lymph node metastasis                      |        |      |                |
| No                                         | 260    | 8.73 | 0.724          | -6.779 <0.001 |
| Yes                                        | 41     | 10.59| 1.732          |        |

*Analysis of variance was performed.

![FIGURE 6](image_url) | The relationship between CKS2 expression and the tumor purity or infiltration level of diverse immune cells in endometrial carcinoma. TPM: transcripts per million.
process or pathway terms enriched by genes negatively co-expressed with CKS2 covered various aspects of cellular functions, including migration, apoptosis, and integrin activation, from which it could be conjectured that the genes positively or negatively correlated with CKS2 may affect the CKS2-centered occurrence and progression of endometrial carcinoma through different biological processes and pathways. Particularly, the impact of CKS2 expression on biological processes such as cell cycle regulation and migration of tumor cells has been verified in other human cancers. The study of Gao et al. demonstrated the G2/M arrest of tongue squamous cell carcinoma cells induced by inhibition of CKS2 expression, and the regulatory effect of CKS2 on the cell cycle progression of tongue squamous cell carcinoma cells was linked with the interaction between CKS2 and DUTPase [24]. Another research on hepatocellular carcinoma unveiled the suppression of knocking down CKS2 expression on the migratory ability of hepatocellular carcinoma cells [25]. The mechanistic bridge between upregulated CKS2 and carcinogenesis of human cancers also involved DNA damage responses and DNA replication. The work of Liberal et al. showed that overexpression of CKS1 or CKS2 in human cancer cells triggered override of the DNA replication blockage under the circumstances of replication stress, enabling DNA replication of cancer cells and thus conferring the advantages in proliferation to boost the development of tumors [26, 27]. The recorded enrichment of CKS2-correlated genes in the above pathways might serve as an explanation for the oncological mechanisms of CKS2 overexpression in endometrial carcinoma.

Aside from the encouraging findings of these works, we were also aware of the limitations of the present study. In vitro and in vivo experiments should be carried out in future work to validate the functional roles of CKS2 in the development of endometrial carcinoma and the genetic interaction of CKS2 with co-expressed genes.

CONCLUSION

In conclusion, we identified the upregulation of CKS2 in endometrial carcinoma with tissue microarrays, RNA-seq, and other public microarrays. The upregulated CKS2 was significantly
related to the clinical progression of endometrial carcinoma patients. The oncogenic effect of CKS2 in endometrial carcinoma might be driven by the abnormal miRNA/TF mediated upstream transcriptional regulation and activities of co-expressed genes in certain molecular functions or pathways.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of Guilin Fanpu Biotech as well as Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

LG conducted data analysis and wrote the manuscript. GC gave advice on the method of design for the manuscript. Z-QL and J-DL contributed to the analysis of microarrays and RNA-seq data. D-ML, Y-LT, DT, and Z-GH checked the results of in-house tissue microarray. J-HC searched in databases and plotted figures. J-YL contributed to proposing methods and performed the data check for the manuscript. J-HZ and Y-WD contributed to the fund-raising and language editing of the manuscript. Z-BF contributed to the design and revision of the manuscript.

FUNDING

This work was supported by Guangxi Medical High-Level Key Talents Training "139" Program (2020), Guangxi Higher Education Undergraduate Teaching Reform Project (2020GA146 and 2021JGA142), Guangxi Educational Science Planning Key Project (2021B167), and Guangxi Zhuang Autonomous Region Health Commission Self-Financed Scientific Research Project (Z20180979 and Z20190529).

CONFLICT OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

ACKNOWLEDGMENTS

We are sincerely thankful for the technical support provided by Guangxi Key Laboratory of Medical Pathology.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.por-journal.com/articles/10.3389/pore.2022.1610307/full#supplementary-material

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71:209–49. doi:10.3322/caac.21660
2. Fader AN, Arriba LN, Frasure HE, von Gruenigen VE Endometrial Cancer and Obesity: Epidemiology, Biomarkers, Prevention and Survivorship. Gynecol Oncol (2009) 114:121–7. doi:10.1016/j.ygyno.2009.03.039
3. Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N Endometrial Cancer. Lancet (2022) 399:1412–28. doi:10.1016/S0140-6736(22)00323-3
4. Zhang K, Li H, Yan Y, Zang Y, Li K, Wang Y, et al. Identification of Key Genes and Pathways between Type I and Type II Endometrial Cancer Using Bioinformatics Analysis. Oncol Lett (2019) 18:2464–76. doi:10.3892/ol.2019.10550

5. Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang Y-R, et al. Type I and II Endometrial Cancers: Have They Different Risk Factors? J Clin Oncol (2013) 31:2607–18. doi:10.1200/JCO.2012.48.2598
6. Eriksson AGZ, Davidson B, Bjerre Trent P, Eyjólfsdóttir B, Dahl GF, Wang Y, et al. Update on Sentinel Lymph Node Biopsy in Surgical Staging of Endometrial Carcinoma. J Clini Med (2021) 10:3094. doi:10.3390/jcm10143094
7. Straubhar AM, Parsons MW, Francis S, Gaffney D, Maurer KA Refusal of Surgery and Survival Outcomes in Endometrial Cancer. Int J Gynecol Cancer (2021) 31:1236–41. doi:10.1136/ijgc-2021-002692
8. Wang H, Li W, Li N Efficacy of Laparoscopic, Pelvic and Para-Aortic Lymphadenectomy in the Treatment of Endometrial Carcinoma. J BUON (2021) 26:1797–801.
9. Jiang P, Yuan R Analysis of Factors Related to Lymph Node Metastasis in Early-Stage Type 1 Endometrial Cancer: Verifying the Clinical Value of Positive Threshold of the Immunohistochemical Parameter Ki67. Cancer Manag Res (2021) 13:6319–28. doi:10.2147/CMAR.S316211
10. Sasano H, Watanabe K, Ito K, Sato S, Yajima A. New Concepts in the Diagnosis and Prognosis of Endometrial Carcinoma. *Pathol Annu* (1994) 29(Pt 2):31–49.

11. Wang J-J, Fang Z-X, Ye H-M, You P, Cai M-J, Duan H-B, et al. Clinical Significance of Overexpressed Cyclin-dependent Kinase Subunit 1 and 2 in Esophageal Carcinoma. *Dis Esophagus* (2013) 26:729. doi:10.1111/dote.12013

12. Wu Z, Lu B, Li X, Miao W, Li J, Shi Y, et al. MicroRNA-26a Inhibits Proliferation and Tumorigenesis via Targeting CKS2 in Laryngeal Squamous Cell Carcinoma. *Clin Exp Pharmacol Physiol* (2018) 45:444–51. doi:10.1111/1440-1681.12890

13. Zhang X-M, Wang J, Liu Z-L, Liu H, Cheng Y-F, Wang T. LINC00657/miR-26a-5p/CKS2 ceRNA Network Promotes the Growth of Esophageal Cancer Cells via the MDM2/p53/Bcl2/Bax Pathway. *Biosci Rep* (2020) 40: BSR20200525. doi:10.1042/BSR20200525

14. Xu JH, Wang Y, Xu D. CKS2 Promotes Tumor Progression and Metastasis and Is an Independent Predictor of Poor Prognosis in Epithelial Ovarian Cancer. *Eur Rev Med Pharmacol Sci* (2019) 23:3225–34. doi:10.26355/eurev_201904_17681

15. Shen D-Y, Zhan Y-H, Wang Q-M, Rui G, Zhang Z-M. Oncogenic Potential of Cyclin Kinase Subunit-2 in Cholangiocarcinoma. *Liver Int* (2013) 33:137–48. doi:10.1111/liv.12014

16. Kita Y, Nishizono Y, Okumura H, Uchikado Y, Sasaki K, Matsumoto M, et al. Clinical and Biological Impact of Cyclin-dependent Kinase Subunit 2 in Esophageal Squamous Cell Carcinoma. *Oncol Rep* (2014) 31:1986–92. doi:10.3892/or.2014.3062

17. Gao L, He R-q., Wu H-y., Zhang T-t., Liang H-w., Ye Z-h., et al. Expression Signatures and Role of miR-30d-5p in Non-small Cell Lung Cancer: a Comprehensive Study Based on In Silico Analysis of Public Databases and In Vitro Experiments. *Cell Physiol Biochem* (2018) 50:1964–87. doi:10.1159/000494875

18. Li G-S, Hou W, Chen G, Yao Y-X, Chen X-Y, Zhang X-G, et al. Clinical Significance of Integrin Subunit Beta 4 in Head and Neck Squamous Cell Carcinoma. *Cancer Biother Radiopharm* (2022) 37:256–75. doi:10.1089/cbr.2020.3943

19. Yang Z, Cheng H, Zhang Y, Zhou Y. Identification of NDRG Family Member 4 (NDRG4) and CDC28 Protein Kinase Regulatory Subunit 2 (CKS2) as Key Prognostic Genes in Adrenocortical Carcinoma by Transcriptomic Analysis. *Med Sci Monit* (2021) 27:e928523. doi:10.12659/MSM.928523

20. Xiao D, Dong S, Yang S, Liu Z. CKS2 and RM12 Are Two Prognostic Biomarkers of Lung Adenocarcinoma. *PeerJ* (2020) 8:e10126. doi:10.7717/peerj.10126

21. Yu MH, Luo Y, Qin SL, Wang ZS, Mu YF, Zhong M. Up-regulated CKS2 Promotes Tumor Progression and Predicts a Poor Prognosis in Human Colorectal Cancer. *Am J Cancer Res* (2015) 5:2708–18.

22. Gao F, Li C, Zhao X, Xie J, Fang G, Li Y. CKS2 Modulates Cell-cycle Progression of Tongue Squamous Cell Carcinoma Cells Partly via Modulating the Cellular Distribution of DUTPase. *J Oral Pathol Med* (2021) 50:175–82. doi:10.1111/jop.13116

23. Zhang J, Song Q, Liu J, Lu L, Xu Y, Zheng W. Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma. *Dis Markers* (2019) 2019:1–13. doi:10.1155/2019/8964015

24. del Rincón SV, Widschwendter M, Sun D, Ekholm-Reed S, Tat J, Teixeira LK, et al. Cks Overexpression Enhances Chemotherapeutic Efficacy by Overriding DNA Damage Checkpoints. *Oncogene* (2015) 34:1961–7. doi:10.1038/onc.2014.137

25. Liberal V, Martinsson-Ahlzén H-S, Liberal J, Spruck CH, Widschwendter M, McGowan CH, et al. Cyclin-dependent Kinase Subunit (Cks) 1 or Cks2 Overexpression Overrides the DNA Damage Response Barrier Triggered by Activated Oncoproteins. *Proc Natl Acad Sci U.S.A* (2012) 109:2754–9. doi:10.1073/pnas.110344108

Copyright © 2022 Gao, Chen, Liang, Li, Tang, Tang, Huang, Chen, Luo, Zeng, Dong and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.